10-Q quarterly report · filed Nov 4, 2026

Abbott Laboratories (ABT) Q3 2026 10-Q Quarterly Report

Short answer

Abbott Laboratories (ABT) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $13.0B (up 14.5% year over year) with net income of $920M.

Q3 2026 key financials · XBRL

Revenue
$13.0B
+14.5% YoY · +3.3% QoQ
Net income
$920M
−44.0% YoY · −0.9% QoQ
Operating margin
10.4%
EPS (diluted)
$0.53
−43.0% YoY · +0.0% QoQ

Source: XBRL data from the Abbott Laboratories (ABT) Q3 2026 10-Q on SEC EDGAR. USD.

Abbott Laboratories Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $13.0B, up 14.5% YoY, with foreign exchange reducing growth by 0.3%
  • Gross margin 50.3% vs 51.7% YoY, pressured by Exact Sciences amortization, higher costs, and foreign exchange
  • Best segment Diagnostic Products, $3.3B, up 46.7%; worst Nutritional Products, $2.3B, up 5.1%
  • Cash $4.1B vs $8.5B at December 31; operating cash flow $5.5B, down approximately $700M YoY
  • Exact Sciences acquisition funded with $20.0B debt; $1.0B share repurchases and $0.63 quarterly dividend per share

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Abbott Laboratories quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.